Recherche Images Maps Play YouTube Actualités Gmail Drive Plus »
Connexion
Les utilisateurs de lecteurs d'écran peuvent cliquer sur ce lien pour activer le mode d'accessibilité. Celui-ci propose les mêmes fonctionnalités principales, mais il est optimisé pour votre lecteur d'écran.

Brevets

  1. Recherche avancée dans les brevets
Numéro de publicationUSRE39498 E1
Type de publicationOctroi
Numéro de demandeUS 09/879,002
Numéro PCTPCT/AU1995/000875
Date de publication27 févr. 2007
Date de dépôt22 déc. 1995
Date de priorité22 déc. 1994
État de paiement des fraisCaduc
Autre référence de publicationCA2208059A1, DE69535418D1, DE69535418T2, EP0799061A1, EP0799061A4, EP0799061B1, WO1996019250A1
Numéro de publication09879002, 879002, PCT/1995/875, PCT/AU/1995/000875, PCT/AU/1995/00875, PCT/AU/95/000875, PCT/AU/95/00875, PCT/AU1995/000875, PCT/AU1995/00875, PCT/AU1995000875, PCT/AU199500875, PCT/AU95/000875, PCT/AU95/00875, PCT/AU95000875, PCT/AU9500875, US RE39498 E1, US RE39498E1, US-E1-RE39498, USRE39498 E1, USRE39498E1
InventeursKarim Rouan Cham, Bill Elliot Cham
Cessionnaire d'origineAruba International Pty. Ltd.
Exporter la citationBiBTeX, EndNote, RefMan
Liens externes: USPTO, Cession USPTO, Espacenet
Treatment for cardiovascular and related diseases
US RE39498 E1
Résumé
A method for the removal of cholesterol, triglycerides and other lipids from animal plasma, serum or other suitable blood fractions, as a discontinuous flow system, the method comprising withdrawing blood from a subject, separating the required fraction from the blood and mixing with a solvent mixture which extracts the lipids from the fraction, after which the delipidated fraction is recombined with the blood cells and returned to the subject, wherein the solvent extraction step is carried out separately and remote from the subject. The delipidated fraction is washed with a second solvent before being recombined with the blood cells. To ensure that the delipidated fraction is free from all extraction solvent, the fraction is mixed with an absorbent specific for the solvent that is being removed. The preferred absorbent is a macroporous polymeric bead contained in the pores of a sintered glass or plastic sphere, the being capable of absorbing organic molecules from an aqueous solution. By treating the plasma, serum or other suitable blood fraction of a patient by these methods, the blood rheology of a patient with impaired blood circulation can be improved. Further, a rapid regression of coronary atherosclerosis occurs.
Images(10)
Previous page
Next page
Revendications(47)
1. A method for the removal of cholesterol, triglycerides and other lipids from animal plasma, serum, or other suitable blood fraction containing apolipoproteins, as a discontinuous flow system, said method comprising connecting a subject to a device for withdrawing blood, withdrawing blood containing blood cells from the subject, separating said fraction from the blood cells and mixing with a solvent mixture which extracts said lipids from the fraction but which does not extract said apolipoproteins from the fraction, after which the delipidated fraction is recombined with the blood cells and returned to the subject, such that the solve it solvent extraction step is carried out separately and remote from the subject while the subject is not still connected to the device for withdrawing blood frown from the subject, wherein the extraction solvent is removed from the delipidated fraction by mixing the delipidated fraction with an absorbent specific for the extraction solvent and wherein the absorbent does not remove said apolipoproteins from the delipilidated delipidated fraction being returned to the subject.
2. A method as defined in claim 1, wherein the extraction solvent is substantially removed from the delipidated fraction by washing with a second solvent.
3. A method as defined in claim 2, wherein the delipidated fraction is washed four times.
4. A method as defined in claim 2, wherein the second solvent is diethyl ether.
5. A method as defined in claim 1, wherein the absorbent is contained in the pores of sintered spheres.
6. A method as defined in claim 5, wherein the sintered spheres are about 2 mm to 5 mm in diameter and the pores of the spheres are less than 50 Å .ANG. in diameter.
7. A method as defined in claim 1, wherein the absorbent is a macroporous polymeric bead for absorbing organic molecules from an aqueous solution.
8. A method as defined in any one of claim 1, wherein the absorbent is held in a chamber which is adapted to allow the delipidated fraction to pass through or over the absorbent at least twice.
9. A porous sintered sphere for use in a method as defined in claim 1, said sphere containing an absorbent in its pores.
10. A sintered sphere as defined in claim 9, wherein the absorbent is a macroporous polymeric bead for absorbing organic molecules from an aqueous solution.
11. A method of changing the blood rheology of an animal with impaired blood circulation whereby the plasma, serum or other suitable blood fraction of the animal has been treated by a method as defined in claim 1.
12. A method for rapid regression of coronary atherosclerosis in an animal whereby the plasma, serum or other suitable blood fraction from the animal is treated by a method as defined in claim 1.
13. A method of removing excessive adipose tissue from an animal whereby the plasma, serum or other suitable blood fraction from the animal is treated by a method as defined in claim 1.
14. A method of removing fat soluble toxins from an animal whereby the plasma, serum or other suitable blood fraction from the animal is treated by a method as defined in claim 1.
15. A method of changing the blood rheology of an animal whereby the plasma or serum of the animal is exchanged for non-autologous plasma or serum wherein said non-autologous plasma or serum has been treated by a method as defined in of claim 1.
16. A method of rapidly regressing coronary atherosclerosis in an animal whereby the plasma or serum of the animal is exchanged for non-autologous plasma or serum wherein said non-autologous plasma or serum has been treated by a method as defined in claim 1.
17. A method of removing excessive adipose tissue from an animal whereby the plasma or serum of the animal is exchanged for non-autologous plasma or serum wherein said non-autologous plasma or serum has been treated by a method as defined in claim 1.
18. A method of removing fat soluble toxins from an animal whereby the plasma or serum of the animal is exchanged for non-autologous plasma or serum wherein said non-autologous plasma or serum has been treated by a method as defined in claim 1.
19. A method for the removal of cholesterol, triglycerides and other lipids from animal plasma, serum, or other suitable blood fraction containing apolipoproteins, a discontinuous flow system, said method comprising connecting a subject to a device for withdrawing blood, withdrawing blood containing blood cells from the subject, separating said fraction from the blood cells and mixing with a solvent mixture which extracts said lipids from the fraction but which does not extract said apolipoproteins from the fraction, after which the delipidated fraction is is recombined with the blood cells and returned to the subject such that the solvent extraction step is carried out separately and remote from the subject while the subject is not still connected to the device for withdrawing blood from the subject, wherein the solvent extraction step comprises:
(a) mixing the solvent mixture containing the fraction with beads, said beads being of a density substantially mid-way between the density of the fraction and the density of the solvent mixture; and
(b) isolating the thus delipidated fraction-containing phase.
20. A method as defined in claim 19, wherein the beads contain entrapped air to obtain the density substantially midway between the density of the fraction and the density of the solvent mixture.
21. A method as defined in claim 20, wherein the density of the beads is about 0.9 g/ml.
22. A batch method for removing lipids from a volume of animal or human plasma, serum, or other suitable blood fraction containing apolipoproteins comprising:
providing the volume of animal or human plasma, serum, or other suitable blood fraction;
admixing the plasma, serum, or other suitable blood fraction with an extraction solvent which extracts the lipids from the plasma, serum, or other suitable blood fraction without extracting the apolipoproteins to form a delipidated fraction;
introducing an absorbent to the delipidated fraction to substantially remove the extraction solvent from the plasma, serum, or other suitable blood fraction; and
separating the absorbent from the delipidated fraction to form a apolipoprotein containing delipidated fraction.
23. A batch method as claimed in claim 22, wherein the extraction solvent is substantially removed from the delipidated fraction by washing at least once with a second solvent.
24. A batch method as claimed in claim 22, wherein the extraction solvent is substantially removed from the delipidated fraction by washing a plurality of times with a second solvent.
25. A batch method as claimed in claim 23, wherein the second solvent is diethyl ether.
26. A batch method as claimed in claim 22, wherein the absorbent is disposed in the pores of sintered spheres.
27. A batch method as claimed in claim 26, wherein the pores of the sintered spheres are less than 50 Å in diameter.
28. A batch method as claimed in claim 22, wherein the absorbent is a macroporous polymeric bead for absorbing organic molecules from an aqueous solution.
29. A batch method as claimed in claim 22, wherein the absorbent is held in a chamber which is adapted to allow the delipidated fraction to pass through or over the absorbent at least twice.
30. A batch method as claimed in claim 22, further comprising:
mixing the apolipoprotein containing delipidated fraction with blood cells derived from an animal or a human to form a treated blood.
31. A batch method as claimed in claim 30, further comprising:
introducing the treated blood into the blood stream of an animal or a human, wherein the apolipoprotein containing delipidated fraction and the blood cells are respectively autologous or non-autologous to the animal or human.
32. A batch method as claimed in claim 22, further comprising:
introducing the apolipoprotein containing delipidated fraction into the blood stream of an animal or a human, wherein the apolipoprotein containing delipidated fraction is autologous or non-autologous to the animal or human.
33. A method of changing the blood rheology of an animal or a human with impaired blood circulation whereby the plasma, serum, or other suitable blood fraction of the animal or the human has been treated by a method as claimed in claim 31.
34. A method for rapid regression of coronary atherosclerosis in an animal or a human whereby the plasma, serum, or other suitable blood fraction from the animal or human is treated by a method as claimed in claim 31.
35. A method of removing excessive adipose tissue from an animal or a human whereby the plasma, serum or other suitable blood fraction from the animal or human is treated by a method as claimed in claim 31.
36. A method of removing fat soluble toxins from an animal or a human whereby the plasma, serum or other suitable blood fraction from the animal or human is treated by a method as claimed in claim 31.
37. A method of changing the blood rheology of an animal or a human whereby the plasma or serum of the animal or human is exchanged for plasma or serum which has been treated by a method as claimed in claim 32.
38. A method of rapidly regressing coronary atherosclerosis in an animal or a human whereby the plasma or serum of the animal or human is exchanged for plasma or serum which has been treated by a method as claimed in claim 32.
39. A method of removing excessive adipose tissue from an animal or a human whereby the plasma or serum of the animal is exchanged for plasma or serum which has been treated by a method as claimed in claim 32.
40. A method of removing fat soluble toxins from an animal or a human whereby the plasma or serum of the animal or human is exchanged for plasma or serum which has been treated by a method as claimed in claim 32.
41. A batch method for removing lipids from a volume of animal or human plasma, serum, or other suitable blood fraction comprising:
providing the volume of animal or human plasma, serum, or other suitable blood fraction;
admixing the plasma, serum, or other suitable blood fraction with an extraction solvent selected from hydrocarbons, ethers, alcohols, esters, amines, or mixtures thereof which extracts the lipids from the plasma, serum, or other suitable blood fraction to form a delipidated fraction;
introducing an absorbent to the delipidated fraction to substantially remove the solvent from the plasma, serum, or other suitable blood fraction; and
separating the absorbent from the delipidated fraction to form a delipidated fraction.
42. A method as claimed in claim 41, wherein the extraction solvent comprises a mixture of an alcohol and an ether.
43. A method as claimed in claim 42, wherein the extraction solvent comprises a butanol.
44. A method as claimed in claim 41, wherein the extraction solvent comprises butan- 1 -ol or butan- 2 -ol.
45. A method as claimed in claim 41, wherein the extraction solvent comprises an ether.
46. A method as claimed in claim 41, wherein the extraction solvent comprises di-isopropyl ether or propyl ether.
47. A method as claimed in claim 41, wherein the extraction solvent comprises 1-butanol and di-isopropyl ether.
Description
CROSS-REFERENCE TO RELATED APPLICATION

This application is a U.S. National Phase Application filed under 35 U.S.C. § 371 based on International Application No. PCT/AU95/00875, having an International Filing Date of Dec. 22, 1995.

TECHNICAL FIELD

THIS INVENTION relates to plasma or serum delipidation in animals (which term shall indicate humans), to a treatment for cardiovascular disease and to removal of excess fat from the animals. In particular, it is directed to the removal of cholesterol, triglycerides and other lipids, and fat soluble toxins—for example, insecticides—from the blood plasma or serum of such animals.

BACKGROUND ART

Cardiovascular diseases are responsible for a significant number of deaths in most industrialised countries.

One such disease is atherosclerosis which is characterised by local fatty thickening in the inner aspects of large vessels supplying blood to the heart, brain and other vital organs. These lesions obstruct the lumen of the vessel and result in ischaemia of the tissue supplied by the vessel. Prolonged or sudden ischaemia may result in a clinical heart attack or stroke from which the patient may or may not recover.

The relationship between dietary lipid, serum cholesterol and atherosclerosis has long been recognised. In many epidemiological studies it has been shown that a single measurement of serum cholesterol has proved to be a significant predictor of the occurrence of coronary heart disease.

Thus diet is the basic element of all therapy for hyperlipidaemia (excessive amount of fat in plasma). However, the use of diet as a primary mode of therapy requires a major effort on the part of physicians, nutritionists, dieticians and other health professionals.

If dietary modification is unsuccessful, drug therapy is an alternative. Several drugs, used singly or in combination, are available. However, there is no direct evidence that any cholesterol-lowering drug can be safely administered over an extended period.

A combination of both drug and diet may be required to reduce the concentration of plasma lipids. Hypolipidaemic drugs are therefore used as a supplement to dietary control.

Many drugs are effective in reducing blood lipids, but none work in all types of hyperlipidaemia and they all have undesirable side effects. There is no conclusive evidence that hypolipidaemic drugs can cause regression of atherosclerosis. Thus, despite progress in achieving the lowering of plasma cholesterol to prevent heart disease by diet, drug therapies, surgical revascularization procedures and angioplasty, atherosclerosis remains the major cause of death in Western Countries.

In view of the above, new approaches have been sought to reduce the amount of lipid in the plasma of homozygotes and that of heterozygotes for whom oral drugs are not effective.

Plasmapheresis (plasma exchange) therapy has been developed and involves replacement of the patient's plasma with donor plasma or more usually a plasma protein fraction. This treatment can result in complications due to the possible introduction of foreign proteins and transmission of infectious diseases. Further, plasma exchange removes all the plasma proteins as well as very low density lipoprotein (VLDL), low density lipoprotein (LDL), and high density lipoprotein (HDL).

It is known that HDL is inversely correlated with the severity of coronary arterial lesions as well as with the likelihood that these will progress. Therefore, removal of HDL is not advantageous.

Known aphaeresis techniques also exist which can remove LDL from plasma. These techniques include absorption of LDL in heparinagarose beads (affinity chromatography) or the use of immobilised LDL-antibodies. Other methods presently available for the removal of LDL involve cascade filtration absorption to immobilised dextran sulphate and LDL precipitation at low pH in the presence of heparin. Each method specifically removes LDL but not HDL.

LDL aphaeresis has, however, disadvantages. Significant amounts of other plasma proteins are removed during aphaeresis and to obtain a sustained reduction in LDL-cholesterol, LDL aphaeresis must be performed frequently (up to once weekly). Furthermore, LDL removal may be counter productive as, low blood LDL levels may result in increased cellular cholesterol synthesis.

To satisfy the need for a method of achieving a reduction in plasma cholesterol in homozygous familial hypercholesterolemia, heterozygous familial hypercholesterolemia and patients with acquired hyperlipidaemia other than by diet, drug therapy, LDL aphaeresis, or a combination of these, an extra corporeal lipid elimination process, termed “cholesterol aphaeresis”, has been developed. In cholesterol aphaeresis, blood is withdrawn from a subject, plasma separated from the blood and mixed with a solvent mixture which extracts lipid from the plasma, after which the delipidated plasma is recombined with the blood cells and returned to the subject.

In more detail, cholesterol aphaeresis results in the removal of fats from plasma or serum. However, unlike LDL aphaeresis, the proteins that transport the fat (apolipoproteins) remain soluble in the treated plasma or serum. Thus the apolipoproteins of VLDL, LDL and HDL are present in the treated plasma or serum. These apolipoproteins, in particular apolipoproteins A1 from the defatted HDL in the plasma or serum, are responsible for the mobilisation of excessive amounts of deposited fats such as cholesterol in arteries, plaques, or excessive amounts of triglycerides, adipose tissue, or fat soluble toxins that are present in adipose tissue. These excessive amount of fats or toxins are transferred to the plasma or serum, bound to the newly assembled lipoproteins. Thus by applying another cholesterol aphaeresis procedure, these unwanted fats or toxins are successively removed from the plasma and thus the body.

The main advantage of this procedure is that LDL and HDL are thus not removed from the plasma but only cholesterol, some phospholipids and considerable triglycerides. U.S. Pat. No. 4,895,558 describes such a system.

While cholesterol aphaeresis has overcome the shortcomings of dietary and/or drug treatments and other aphaeretic techniques, existing apparatus for cholesterol aphaeresis does not provide a sufficiently rapid and safe process. For use in a clinical setting, apparatus is required which effects delipidation more efficiently. Furthermore, flow rates of the order of 70 ml/min are required for cholesterol aphaeresis of a human subject.

Thus the cholesterol aphaeresis described in the aforementioned U.S. Pat. No. 4,895,558 was improved by incorporating into the system a spinner to disperse the incoming plasma laterally into the extracting solvent in the form of fine droplets to improve separation efficiency. This improved system is described in International Patent Application No. PCT/AU94/00415.

Unfortunately, practice has established that the cholesterol aphaeresis systems described above still suffer from a number of disadvantages.

The first disadvantage is the explosive nature of the solvents used to delipidate this plasma. These solvents are, by the very nature of the continuous systems, in close proximity to the patient and medical staff. This hazard is clearly present for the duration of the delipidation process which usually runs for several hours.

The second disadvantage is that, in the prior continuous systems, a reliable procedure is not available to remove totally all of the solvents used in the delipidation before the treated plasma is returned to the patient.

In particular, the use of the preferred solvent 1-butanol in the delipidation is of concern as it can now be established that that solvent can be present as 1% to 5% of the treated plasma that is returned to the patient. This is because continuous systems can only include a single wash to remove solvents such as 1-butanol and a single wash is now found to be sufficient. It is not possible to provide sequential multi-washes in a continuous system because the patient would have to supply an unacceptable volume of blood to maintain each stage of the system overall and the patient would also be subjected to an increased hazard factor from the prolonged exposure to the solvents.

The long term toxicity of 1-butanol is not known, especially when directly present in the blood stream—it may cross the blood brain barrier. Certainly, external contact with this solvent is known to cause irritation of mucous membranes, contact dermatitis, headaches, dizziness and drowsiness.

A third disadvantage is that the continuous systems described above are not suitable for the delipidation of serum. If serum can be delipidated, there would be the advantage of favourably altering the blood rheology in that the viscosity will decrease following delipidation resulting in better haemodynamics for the originally impaired blood circulation.

Yet a fourth disadvantage is that delipidation in a continuous system is undertaken over several hours. Apart from the prolonged exposure to the hazardous solvents as discussed above, the equipment and staff are committed to a single patient. As the removal of plasma or other blood fractions and their subsequent return to the patient as individual steps each only take a few minutes, it would be advantageous if the relatively lengthy delipidation step could be undertaken off site, thus freeing the patient, medical staff and equipment for other matters.

Finally, in a continuous system, clearly it is only the patient's own blood fraction that can be returned to that patient. However, for example, if the patient's plasma or serum could be removed and treated remote from the patient, then either autologous or non-autologous plasma or serum could be returned to the patient at a later date.

SUMMARY OF THE INVENTION

It is an object of the present invention to overcome, or at least ameliorate, the above-mentioned disadvantages in the provision of a method for delipidating not only plasma but also serum and other blood fractions which substantially reduces the exposure of the patient to the potentially hazardous solvents used, which also can effectively remove all traces of solvent(s) used in that delipidation, and which significantly reduces the contact time between the patient and the actual delipidation process.

It is a further object to provide a method whereby advantageous changes to the blood rheology of the originally impaired blood circulation of the patient can be achieved.

It is yet another object to provide a method whereby a patient's Plasma or serum can be treated remote from that patient, thus allowing either autologous or non-autologous plasma or serum to be returned to the patient at a later date.

In one aspect of the present invention, there is provided a method for the removal of cholesterol, triglycerides and other lipids from animal plasma, serum or other suitable blood fractions, as a discontinuous flow system, said method comprising withdrawing blood from a subject, separating the required fraction from the blood and mixing with a solvent mixture which extracts the said lipids from the fraction, after which the delipidated fraction is recombined with the blood cells and returned to the subject, characterised in that the solvent extraction step is carried out separately and remote from the subject.

Preferably, as part of the solvent extraction step, beads are used when mixing the blood fractions with the solvent. More preferably, the beads have a density substantially mid-way between the density of the fraction and the density of the solvent mixture. This ensures efficient mixing with a large surface area, increasing the efficiency of the extraction and also serving as a good separator of the plasma from the solvent when centrifugation is used to isolate the phases after extraction.

Preferably, to obtain a density substantially mid-way between the density of the fraction and the density of the solvent mixture, the beads contain entrapped air.

More preferably, as the density of plasma is approximately 1.006 g/ml and the solvents used generally have a density of approximately 0.8 g/ml, the density of the beads will be around 0.9 g/ml.

The beads may be manufactured from any acceptable material such as glass or plastic.

Once the resultant delipidated fraction-containing phase has been isolated, all traces of the extraction solvent must be removed before the fraction is recombined with the blood cells and/or returned to the subject.

One way of removing this solvent is to wash with another solvent, preferably diethyl ether, to remove substantially all of the original solvent used in the extraction step.

More preferably, four (4) washes are undertaken.

However, as another aspect of the present invention, efficient removal of the extraction solvent can be achieved by mixing the delipidated fraction with an absorbent specific for the solvent that is being removed.

In particular, the absorbent is contained in the pores of sintered spheres.

More preferably, the sintered spheres are approximately 2 to 5 mm in diameter with the pores of the spheres being less than 50 Å in diameter. Most preferably, the spheres are manufactured from glass.

Preferably, the absorbents used in the sintered spheres are the macroporous polymeric beads for absorbing organic molecules from aqueous solutions marketed by Bio-Rad Laboratories under the trade name Bio-Beads SM.

If the solvent used to delipidate the fraction is 1-butanol, then the absorbent is preferably Bio-Beads SM-2.

Preferably, the absorbent is held in a chamber which is adapted to allow the delipidated fraction to pass through or over the absorbent at least twice if a single pass is insufficient to remove all of the solvent.

Preferably, as part of isolating the delipidated fraction-containing phase, that phase is subsequently washed with another solvent, preferably diethyl ether, to remove a substantial amount of the original solvent before the treatment with the absorbent.

More preferably, that phase is washed at least three (3) times.

The plasma may be human plasma or plasma from other living animals. The plasma can be obtained from human or animal blood by known plasma separating techniques which include centrifugal separation, filtration and the like.

Similarly, the serum or other lipid-containing fraction can be derived from human or other living animals by known techniques.

Suitable solvents for the extraction comprise mixtures of hydrocarbons, ethers and alcohols. Preferred solvents are mixtures of lower alcohols with lower ethers. The lower alcohols suitably include those which are not appreciably miscible with the plasma and these can include the butanols (butan-1-ol and butan-2-ol). C1-4 ethers are also preferred and these can include the propyl ethers (di-isopropyl ether and propyl ether). Other solvents which may be applicable include amines, esters, hydrocarbons and mixtures providing that the solvent can (1) rapidly and preferably remove cholesterol from the plasma, (2) is substantially immiscible with the plasma, (3) can be removed from the plasma, and (4) does not denature the desired moieties. Preferred solvent compositions are butanol with di-isopropyl ether and these may be in the ratio of 0%-40% of the alcohol to 100%-60% of the ether.

DETAILED DESCRIPTION OF EMBODIMENTS Materials and Methods

Animals

The roosters used in this study were of White Leghorn Hiline strain and were obtained as one-day old chicks. All roosters from 8 weeks old were transferred into individual cages. Water and feed were supplied unrestricted. At eight weeks of age, 15 control birds were fed a commercial poultry ration for 31 days and another group of 30 birds were injected subcutaneously each day with 5 mg diethylstilboestrol (DES) in sesame oil for a period of 31 days. In addition they were fed on the same commercial diet which was supplemented with 2.6% (w/w) cholesterol for a period of 31 days. Fifteen animals of the DES treated group were then subjected to lipid aphaeresis (LA). Fifteen animals of the DES treated group had sham treatments. Once the LA or sham treatments commenced, all animals were fed the standard poultry ration, except during the actual treatment itself when animals were kept off their feed for three hours following reinfusion of their autologous blood. Animals were sacrificed two days following the 4th treatment, LA or sham.

Lipid Aphaeresis Procedure

Approximately 25% of the calculated blood volume was collected from a brachial vein of the animal with a 21 gauge needle and syringe. The total blood volume was estimated at 8 percent of the body weight. The blood was collected in heparinized tubes and immediately centrifuged at 900 g for 5 minutes at room temperature. The blood cells were suspended in an amount of saline equivalent to the plasma volume and were reinfused into the animal. The plasma was kept refrigerated for twelve hours and was then delipidated for 20 minutes with a mixture of butanol and di-isopropyl ether (DIPE), 25:75 (v/v), in a ratio of one volume of plasma to two volumes of butanol-DIPE mixture (organic phase). Inert plastic beads with a density of 0.9 g/mL (1 g) were added to the mixture. After extraction, the mixture was centrifuged at 900 g for 2 min to separate the plasma and organic phases. The organic phase (upper layer) was removed, free of plasma phase, by careful aspiration with a pasteur pipette under vacuum. Traces of butanol in the plasma phase were washed out with four volumes of diethyl ether (DEE) for 2 min by end-over-end rotation at 30 rpm. The mixture was then centrifuged at 900 g for 2 min to separate plasma and ether phases. The ether phase was subsequently removed by aspiration with a pasteur pipette. Residual ether was removed by evacuation with a water pump aspirator at 37° C. The plasma was then passed through a 5 mL column containing Bio-Beads SM-2.

This procedure yielded delipidated plasma. The delipidated plasma was re-mixed with the blood cells of a subsequent 25% blood collection which was then reinfused through a brachial vein back into the identical donor animals. The duration of the entire procedure, that is, removal of blood from the animal to reinfusion of treated blood back to the animal was approximately 1 hour. After the fourth lipid aphaeresis treatment, the animals were sacrificed and their livers and aortae were dissected. The LA treatment procedures were repeated 3 times after the first treatment.

Sham Treatment Procedures

This was essentially the same as the LA procedure with the exception of the plasma delipidation with the organic solvents. The blood was collected in heparinized tubes and immediately centrifuged at 900 g for 5 min. The plasma was separated from the blood cells. The blood cells were mixed with saline in the same volume of the collected plasma and reinfused into the animal. The plasma was kept refrigerated for twelve hours and was then remixed with blood cells of a subsequent 25% blood collection after the second and/or subsequent plasma separations. After the fourth lipid aphaeresis treatment, the animals were sacrificed and their livers and aortae were dissected. The sham treatment procedures were repeated 3 times after the first treatment.

Tissue Lipid Preparation

The livers were weighed, minced with a scalpel blade and homogenised in 0.9% sodium chloride solution by 10-12 strokes of a motor driven Teflon-glass homogeniser (1900 rpm). The aorta was weighed and three times its weight of 3 mm glass beads were added in a homogenising bottle containing 0.9% sodium chloride. The contents were then homogenised for one minute. The lipid from the homogenised liver and aorta samples were extracted by the Folch procedure and weighed.

TABLE I
Effect of LA and sham treatments on the
total lipid concentrations in livers and
aortas of hyperdiedemic roosters
TREATED
UNTREATED FOUR APHAFRESIS APPLICATIONS
CONTROLS SHAM LA
n = 15 n = 15 n = 15
LIVERa 3.65 ± 0.98 5.53 ± 1.50b 3.72 ± 1.002
AORTAc 6.01 ± 0.97 0.11 ± 2.15c 0.32 × 0.95d
aTotal lipid concentrations expressed as g lipid per 100 g tissue, mean ± SD
b,cp values were <0.05 when sham treatments were compared with LA treatments.
There were no statistical differences between the values of corresponding tisues in the untreated control group and the LA treated group.
All animals were sacrificed two days after the final apherical treatment.

Humans

Patients have the plasmapheresis procedure undertaken using known transvenous techniques and plasmapheresis systems.

Plasmapheresis is performed using vein-to-vein or arteriovenous fistula in the forearm of patients. Heparin is given at the beginning of the procedure as a 5,000 unit bolus, and then by continuous infusion at the rate of 700 units per hour over the course of the procedure. Access through the antecubital veins should provide plasma flow rates of 25 to 40 mls per minute.

Blood taken from a patient is immediately treated with ACD-A (anticoagulant) in a ratio of between 1:8 and 1:16 (ACD-A:blood). The plasma is separated from this solution using a conventional plasmapheresis machine.

Twenty five percent plasma is removed from the patient. This represents one percent of the ideal body weight.

Only the first volume of plasma collection is replaced with plasma replacement fluid to the patient.

The plasma is kept refrigerated up until twelve hours prior to reinfusion of delipidated plasma in exchange for another twenty five percent plasma collection (weekly or biweekly).

The plasma is delipidated and the delipidated plasma is tested to ensure all solvent has been removed before the clean delipidated plasma is exchanged for new untreated plasma.

In one embodiment of the present invention, the continuous flow system described in U.S. Pat. No. 4,895,558 (the entire content of which is included herein) is modified to a discontinuous system by removing the appropriate blood volume to be treated and subjecting that volume to delipidation at a site remote from the patient.

In another embodiment of the present invention, the continuous flow system described in International Patent Application No. PCT/AU94/00415 (the entire content of which is included herein) is modified to a discontinuous system by removing the appropriate blood volume to be a site remote from the patient before the plasma is dispersed into small droplets into the solvent by the dispersing means.

In either of the above embodiments, the extraction step can include, in accordance with the present invention, either multiple washing of the extracted phase and/or using an absorbent.

For example, the plasma is delipidated with a solvent mixture comprising 1-butanol and di-isopropyl ether. The delipidated fraction is then washed three (3) or four (4) times with diethyl ether. After the final wash, the diethyl ether is removed by centrifugation and vacuum extraction at 37° C. The sintered spheres containing Bio-Beads SM-2 are then mixed with the delipidated plasma to remove the final traces of 1-butanol.

Conclusions

DES administration to the roosters resulted in a significant amount of fat (lipid) accumulation in the livers and aortae.

Discontinuous LA treatments corresponding to approximately one plasma volume treated by four applications of 25% of plasma volume treated per time resulted in significant decreases in both hepatic and aortic lipids in hyperlipidaemic animals. Moreover, the LA treated hyperlipidaemic animals ended up with lipid values that were similar to control animals.

    • (i) These experiments show that excessive amounts of body fats in the form of adipose tissue (triglycerides) in the liver can be removed by LA; and
    • (ii) regression of atherosclerosis occurs in the aorta by LA treatments.

Similar results can be expected for human patients.

By adapting the prior art methods to discontinuous flow systems, the present invention can remove or at least significantly reduce any danger to patients and medical staff from the explosive nature of the solvents employed.

Further, by using the improved solvent extraction methods of the present invention, all of the potentially poisonous extraction solvents can be removed before the treated blood is returned to the patient.

Also, the improved solvent extraction method of the present invention is not limited to plasma delipidation but also it is applicable to the delipidation of serum, thus providing advantageous changes to the blood rheology of the originally impaired blood circulation of the patient.

The present invention thus provides for a rapid regression of coronary atherosclerosis in a patient.

Finally, as the present invention is a discontinuous system, it is not essential to return the delipidated blood fraction immediately to the patient. It is already known that plasma or serum can be collected and stored under sterile conditions in a refrigerator or freezer for extended periods and that it can be returned safely to the patient within twelve (12) hours of breaking the sterile seal. Therefore, if necessary, reintroduction of the delipidated fraction can occur several weeks after it was first removed from the patient. This option leads to particular advantages such as, economies of scale when several patients have to be treated simultaneously, the freeing of medical staff and equipment for other duties, and the reduction in stress for the patient whom no longer has to be hooked up to a delipidation apparatus for several continuous hours. Further, it enables a bank of plasma or serum to be maintained which is free of any infection which can be delipidated and exchanged for a patient's plasma or serum as required. Of course, autologous or non-autologous plasma or serum could be returned to the patient under these conditions.

The embodiments are described by way of illustrative examples only and various changes and modifications may be made thereto without departing from the inventive concept as defined in the following claims.

Citations de brevets
Brevet cité Date de dépôt Date de publication Déposant Titre
US364762424 juil. 19697 mars 1972Wisconsin Alumni Res FoundTreatment of blood with oleaginous substance
US39589398 janv. 197525 mai 1976Coulter Electronics, Inc.Method for clarification of lipemic serum
US398300820 mai 197528 sept. 1976Idemitsu Kosan Co., Ltd.Method of extracting useful components from microbial cells
US398946613 août 19732 nov. 1976Pan Samuel CLiquid-liquid extraction apparatus including fibrous strand packing
US40254239 janv. 197624 mai 1977Metallgesellschaft AktiengesellschaftProcess for removing monohydric and polyhydric phenols from waste water
US41036855 janv. 19761 août 1978Lupien Paul JMethod and apparatus for extravascular treatment of blood
US412450914 avr. 19777 nov. 1978Asahi Medical Co., Ltd.Haemodialyzer employing hollow fibers
US423431724 mai 197918 nov. 1980Analytical Products, Inc.Apparatus and method for fractionation of lipoproteins
US42356025 mars 197925 nov. 1980Krebs & CieInstallation for mixing and separating two non-miscible liquids, inter alia for liquid-liquid extraction
US42580107 nov. 197724 mars 1981Eszakmagyarorszagi Vegyimu_ vekSolvent extraction apparatus
US435015629 mai 198021 sept. 1982Japan Foundation For Artificial OrgansMethod and apparatus for on-line filtration removal of macromolecules from a physiological fluid
US439171119 mars 19815 juil. 1983Davy Mckee (Minerals & Metals) LimitedMethod of, and apparatus for, effecting liquid-liquid contact
US439921730 avr. 198016 août 1983Laboratoires GoellaProcess and a device for the determination of serum lipoproteins
US440294017 sept. 19826 sept. 1983Kuraray Co., Ltd.Method for treating blood plasma employing a hollow fiber membrane
US443528923 déc. 19816 mars 1984Romicon, Inc.Series ultrafiltration with pressurized permeate
US44639887 sept. 19827 août 1984Cities Service Co.Horizontal heated plane process
US448118914 avr. 19826 nov. 1984New York Blood Center Inc.Process for preparing sterilized plasma and plasma derivatives
US45228091 août 198411 juin 1985Institut PasteurProcess for obtaining lipid envelope virus sub-units, notably antigens for use as vaccines, the products obtained and their applications
US454040122 févr. 198310 sept. 1985Applied Immune Sciences, Inc.In vivo therapeutic apheresis using lipid vesicles
US454057314 juil. 198310 sept. 1985New York Blood Center, Inc.Undenatured virus-free biologically active protein derivatives
US458123131 août 19838 avr. 1986The United States Of America As Represented By The Secretary Of Health And Human ServicesInactivation of viruses containing essential lipids
US459150521 févr. 198427 mai 1986New York Blood Center, Inc.Process for inactivating hepatitis B virus
US461350121 déc. 198423 sept. 1986New York Blood Center, Inc.Inactivation of viruses in labile blood derivatives
US461588618 mai 19847 oct. 1986The United States Of America As Represented By The Secretary Of The Department Of Health & Human ServicesUtilizing a halohydrocarbon containing dissolved water to inactivate a lipid virus
US464371823 juil. 198517 févr. 1987Applied Immunesciences, Inc.Therapeutic apheresis
US46455126 mai 198524 févr. 1987The Dow Chemical CompanyContinuous process for removing water-soluble particles from organic liquids
US46472802 juil. 19863 mars 1987Akzo NvBinder for low density lipoproteins
US4648974 *14 mars 198410 mars 1987Intermedicat GmbhProcess for the selective extracorporeal separation of blood constituents
US466839814 août 198526 mai 1987Colgate-Palmolive CompanyContinuous extraction apparatus and process
US46719099 août 19849 juin 1987Torobin Leonard BMethod for making hollow porous microspheres
US467690514 déc. 197630 juin 1987Toray Industries, Inc.Fluid separation method and apparatus
US467705711 mars 198530 juin 1987Scripps Clinic And Research FoundationDiagnostic assay for the presence of apolipoproteins associated with plasma high density lipoproteins
US46803206 déc. 198514 juil. 1987Kanegafuchi Kagaku Kogyo Kabushiki KaishaMethod for preparation of droplets
US46966706 nov. 198529 sept. 1987Kanegafuchi Kagaku Kogyo Kabushiki KaishaMethod and apparatus for treating blood constituents
US477548318 sept. 19864 oct. 1988Canadian Patents And Development Ltd.Method to reduce plasma cholesterol
US48320349 avr. 198723 mai 1989Pizziconi Vincent BMethod and apparatus for withdrawing, collecting and biosensing chemical constituents from complex fluids
US483692826 avr. 19856 juin 1989Terumo Kabushiki KaishaSeparation method, separation device and separation apparatus for separating body fluid into respective components
US487903717 mars 19887 nov. 1989Utzinger Gustav EMethod and apparatus for counter current liquid-liquid extraction
US4895558 *20 janv. 198823 janv. 1990University Of QueenslandAutologous plasma delipidation using a continuous flow system
US4908354 *20 nov. 198713 mars 1990B. Braun-Ssg AgProcess for the selective extracorporeal precipitation of low-density lipoproteins
US490994030 déc. 198720 mars 1990New York Blood Center, Inc.Extraction of process chemicals from labile biological mixtures with organic alcohols or with halogenated hydrocarbons
US490994212 oct. 198820 mars 1990Tanabe Seiyaku Co., Ltd.Process for removing pyrogens
US492343923 mars 19888 mai 1990B. Braun-Ssc AgProcess for the selective extracorporeal precipitation of low-density lipoproteins from whole serum or plasma
US4935204 *14 nov. 198819 juin 1990B. Braun-Ssc AgProcess and device for the specific adsorption of heparin
US496670918 juil. 198830 oct. 1990The Cleveland Clinic FoundationThermofiltration of plasma
US497014426 déc. 198513 nov. 1990International Genetic EngineeringPeptide fragments of human apolipoprotein, type-specific antibodies and methods of use
US502647913 févr. 199025 juin 1991Union Carbide Industrial Gases Technology CorporationFluid separation device
US508079612 févr. 199014 janv. 1992The Cleveland Clinic FoundationThermofiltration of plasma
US508960211 mars 199118 févr. 1992Rotkreuzstiftung Zentrallaboratorium Blutspendedienst SrkProcess for the manufacture of apolipoproteins from human blood plasma or serum
US511295617 mars 198912 mai 1992The Nutrasweet CompanyMethod for extraction of lipids and cholesterol
US51163079 juil. 199026 mai 1992Collins Harvey TMethod and system for treatment of AIDS
US512624029 sept. 198630 juin 1992Curtiss Linda KHybridomas and monoclonal paratopic molecules to apolipoprotein a-i
US512831827 oct. 19887 juil. 1992The Rogosin InstituteReconstituted HDL particles and uses thereof
US515274320 août 19906 oct. 1992Healthdyne, Inc.Apparatus and method for selective separation of blood cholesterol
US518701027 nov. 199016 févr. 1993W. R. Grace & Co.-Conn.Membrane having high affinity for low density lipoprotein-cholesterol from whole blood
US520377817 oct. 199120 avr. 1993Boehringer LaboratoriesProcess and apparatus for removal of insoluble fat from blood of a patient
US521185026 juil. 199118 mai 1993Research Medical, Inc.Plasma filter sorbent system for removal of components from blood
US523664431 oct. 199117 août 1993W. R. Grace & Co.-Conn.Process of making membrane for removal of low density lipoprotein-cholesterol from whole blood
US525676710 nov. 199226 oct. 1993The Immune Response CorporationRetroviral antigens
US52581495 mai 19922 nov. 1993W. R. Grace & Co.-Conn.Process of making a membrane for high efficiency removal of low density lipoprotein-cholesterol from whole blood
US5279540 *24 sept. 199218 janv. 1994Davidson Michael HMethod for reducing the risk of atherosclerosis
US530169412 nov. 199112 avr. 1994Philip Morris IncorporatedProcess for isolating plant extract fractions
US535426222 févr. 199311 oct. 1994Boehringer LaboratoriesApparatus for removal of insoluble fat from blood of a patient
US539114312 mars 199321 févr. 1995Kensey Nash CorporationMethod and system for effecting weight reduction of living beings
US53934292 nov. 199228 févr. 1995Jgc CorporationLiquid-liquid contactor
US5401415 *11 juin 199128 mars 1995B. Braun Melsungen AgAdsorption material for the selective removal of LDL and/or vLDL and method of using therefor
US54014661 juin 199328 mars 1995Miles Inc.Device for the direct measurement of low density lipoprotein cholesterol
US541806121 juil. 199323 mai 1995W. R. Grace & Co.-Conn.Microporous polysulfone supports suitable for removal of low density lipoprotein-cholesterol
US541975927 mai 199330 mai 1995Naficy; Sadeque S.Apparatus and methods for treatment of HIV infections and AIDS
US5424068 *5 mars 199313 juin 1995P. Doina International Ltd.Method for immunization of mammals against atherosclerosis and pharmaceutical compositions for obtaining said immunization
US547671528 sept. 199319 déc. 1995Fresenius AgParticulate adsorbent for the removal of biomacromolecules such as LDL and endotoxins from whole blood in extracorporeal circuits
US548439617 nov. 198816 janv. 1996Naficy; Sadeque S.Method and device for treatment of HIV infections and AIDS
US549663730 avr. 19935 mars 1996W. R. Grace & Co.-Conn.High efficiency removal of low density lipoprotein-cholesterol from whole blood
US55230966 juin 19954 juin 1996Applied Immune Sciences, Inc.Removal of selected factors from whole blood or its components
US563489324 avr. 19953 juin 1997Haemonetics CorporationAutotransfusion apparatus
US563722414 sept. 199410 juin 1997New Jersey Institute Of TechnologyHollow fiber contained liquid membrane pervaporation for removal of volatile organic compounds from aqueous solutions
US565233921 déc. 199429 juil. 1997Rotkreuzstiftung ZentrallaboratoriumMethod of producing reconstituted lipoproteins
US5679260 *26 sept. 199521 oct. 1997B. Braun Melsungen AgProcess for simultaneously removing tumour necrosis factor α and bacterial lipopolysaccharides from an aqueous liquid
US569843211 oct. 199616 déc. 1997Retroscreen Ltd.Vaccines and methods for their production
US57076734 oct. 199613 janv. 1998Prewell Industries, L.L.C.Process for extracting lipids and organics from animal and plant matter or organics-containing waste streams
US57191947 juin 199617 févr. 1998Ausimont S.P.A.Prevention and treatment of topical viral infections with perfluoropolyethers or compositions thereof
US574403822 juil. 199428 avr. 1998Aruba International Pty Ltd.Solvent extraction methods for delipidating plasma
US575322723 juil. 199319 mai 1998Strahilevitz; MeirExtracorporeal affinity adsorption methods for the treatment of atherosclerosis, cancer, degenerative and autoimmune diseases
US585372526 avr. 199429 déc. 1998The Immune Response CorporationPrevention and treatment of retroviral disease
US585578210 août 19945 janv. 1999Falkenhagen; DieterArrangement for removing substances from liquids, in particular blood
US58582387 mars 199712 janv. 1999Baxter Research Medical, Inc.Salvage of autologous blood via selective membrane/sorption technologies
US587700525 oct. 19952 mars 1999Aphios CorporationViral inactivation method using near critical, supercritical or critical fluids
US58855785 juin 199523 mars 1999The Immune Response CorporationPrevention and treatment of retroviral disease
US58956505 juin 199520 avr. 1999The Immune Response CorporationPrevention and treatment of retroviral disease
US591169822 déc. 199515 juin 1999Aruba International Pty. Ltd.Treatment for cardiovascular and related diseases
US59168065 juin 199529 juin 1999The Immune Response CorporationPrevention and treatment of retroviral disease
US591936916 juil. 19966 juil. 1999Hemocleanse, Inc.Hemofiltration and plasmafiltration devices and methods
US59289305 juin 199527 juil. 1999Immune Response CorporationPrevention and treatment of retroviral disease
US59484413 janv. 19957 sept. 1999The Liposome Company, Inc.Method for size separation of particles
US596232215 nov. 19965 oct. 1999Massachusetts Institute Of TechnologyMethods for modulation of cholesterol transport
US598047810 oct. 19979 nov. 1999Transvivo, Inc.Apparatus and method for the treatment of acute and chronic renal disease by continuous passive plasma ultrafiltration
US60175435 juin 199525 janv. 2000The Immune Response CorporationPrevention and treatment of retroviral disease
US60223331 mai 19978 févr. 2000S.L.I.M. Tech, Ltd.Method and system for removing materials from lymphatic and other fluids
US603745822 sept. 199214 mars 2000Kanegafuchi Kagaku Kogyo Kabushiki KaishaAdsorbent for serum amyloid protein
US603994620 juil. 199421 mars 2000Strahilevitz; MeirExtracorporeal affinity adsorption devices
US619389120 déc. 199627 févr. 2001American National Red CrossMethods for the selective separation of organic components from biological fluids
US630955022 juin 199530 oct. 2001Fls Miljo A/SMass transfer method and apparatus
CA1271708A5 sept. 198617 juil. 1990Reinhard GluckProcess for the preparation of a rabies vaccine and the vaccine obtained by this process
CN1189378A30 déc. 19975 août 1998长春市中心血站Application and prodn. method of HDL preparation
DE2944138A12 nov. 197911 juin 1981Technicon GmbhAutomatic analysis of separation of deposits from liquids - is by extracting fraction of flowing segmented sample following sedimentation
DE3118072A17 mai 198125 nov. 1982Heuck Claus Christian Dr Rer NProcess for separating lipophilic constituents from aqueous colloid solutions for preparative purposes and/or for detecting an analyte in the aqueous phase
DE3213390A110 avr. 198220 oct. 1983Schurek Hans JoachimVorrichtung zur bilanzierung des fluessigkeitsaustausches bei haemofiltrationen
WO1995003840A1 *22 juil. 19949 févr. 1995The University Of QueenslandA plasma delipidation system
Citations hors brevets
Référence
1Agnese, S.T. et al. , "Evaluation of Four Reagents for Delipidation of Serum", Clinical Biochemistry, 16(2): pp. 98-100 (1983).
2Albouz, S. et al. , "Extraction of Plasma Lipids Preserving Antigenic Properties of Proteins and Allowing Quantitation of Gangliosides by Neuraminic Acid Determination", Ann. Biol. Clin. (Paris) (4ZS), 37(5): pp. 287-290 (1979).
3Asztalos et al., Arterioscler. Thromb. Vasc. Biol., Presence and Formation of 'Free Apolipoprotein A-I-Like' Particles in Human Plasma, 15, 1419-1423,. (1995).
4Asztalos et al., Arterioscler. Thromb. Vasc. Biol., Role of Free Apolipoprotein A-I in Cholesterol Efflux, 17, 1630-1636. (1997).
5Badimon, J.J. et al. , "High Density Lipoprotein Plasma Fractions Inhibit Aortic Fatty Streaks in Cholesterol-Fed Rabbits", Laboratory Investigation, vol. 60, No. 3: pp. 455-461 (1989).
6Badimon, J.J. et al. , "Regression of Atherosclerotic Lesions by High Density Lipoprotein Plasma Fraction in the Cholesterol-Fed Rabbit", J. Clinical Investigation, vol. 85, No. 4: pp. 1234-1241 (1990).
7Barrans et al., Biochimica et Biophysica Acta, Pre-beta HDL: Structure and Metabolism, 1300, 73-85. (1996).
8Bloom, et al. "Quantitation of lipid profiles from isolated serum lipoproteins using small volumes of human serum." Clin Biochem 1981 Jun;14(3): 119-25.
9Cham, B.E. et al. , "Changes in Electrophoretic Mobilities of alpha-and beta-Lipoproteins as a Result of Plasma Delipidation", Clinical Chemistry, 22: pp. 305-309 (1976).
10Cham, B.E. et al. , "In Vitro Partial Relipidation of Apolipoproteins in Plasma", J. Biol. Chem., 251 (20): pp. 6367-6371 (1976).
11Cham, B.E., et al. , "A Solvent System for Delipidation of Plasma or Serum Without Protein Precipitation", J. of Lipid Research, vol. 17: pp. 176-181 (1976).
12Cham, B.E., et al. , "Importance of Apolipoproteins in Lipid Metabolism", Chem. Biol. Interactions, 20: pp. 263-277 (1978).
13Cham, B.E., et al. , "Lipid Apheresis in an Animal Model Causes In Vivo Changes in Lipoprotein Electrophoretic Patterns", J. Clin. Apheresis, 11 (2): pp. 61-70 (1996).
14Cham, B.E., et al. , "Lipid Apheresis: An In Vivo Application of Plasma Delipidation with Organic Solvents Resulting in Acute Transient Reduction of Circulating Plasma Lipids in Animals", J. Clin. Apheresis 10: pp. 61-69 (1995).
15Cham, B.E., et al., "Heterogeneity of Lipoprotein B", Biochemical and Biophysical Research Communications, vol. 103, No. 1: pp. 196-206 (1981).
16Cham, B.E., et al., "Lipid Apheresis in an Animal Model Causes Acute Reduction in Plasma Lipid Concentrations and Mobilisation of Lipid from Liver and Aorta", Pharmacol. (Life Sci. Adv.)13: pp. 25-32 (1994).
17Cham, B.E., et al., "Phospholipids in EDTA-Treated Plasma and Serum", Clinical Chemistry, vol. 39, No. 11: pp. 2347-2348 (1993).
18Cham, B.E., et al., "Rapid Regression of Atherosclerosis by Cholesterol Apheresis-A Newly Developed Technique", 59<SUP>th </SUP>Congress European Atherosclerosis Society, Nice France, May 17-21, 1992.
19Cham, B.E., et al., "Rapid, Sensitive Method for the Separation of Free Cholesterol from Ester Cholesterol", Clinica Chimica Acta, 49: pp. 109-113 (1973).
20Cham, B.E., Nature of the Interaction Between Low-Density Lipoproteins and Polyanions and Metal Ions, as Exemplified by Heparin and Ca<SUP>2+</SUP>, Clinical Chemistry, vol. 22, No. 11: pp. 1812-1816 (1976).
21Collet et al., Journal of Biological Chemistry, Differential Effects of Lecithin and Cholesterol on the Immunoreactivity and Confirmation of Apolipoprotein A-I in High Density Lipoproteins, 266 (14), 9145-9152. (May 15, 1991).
22Cruzado et al., Analytical Biochemistry, Characterization and Quantitation of the Apoproteins of High-Density Lipoprotein by Capillary Electrophoresis, 14 (7), 100-109. (1996).
23Deva, et al., J. Hosp. Infect., Establishment of an in-use testing method for evaluating disinfection of surgical instruments using the duck hepatitis B model , 22, 119-130. (abstract only) (Jun. 1996).
24Dwivedy, A.K., "Increase of Reverse Cholesterol Transport by Cholesterol Apheresis: Regression of Atherosclerosis", 18<SUP>th </SUP>Australian Atherosclerosis Society Conference, Surfers Paradise, p. 21 (1992).
25Eisenhauer, T. et al. , "Selective Removal of Low Density Lipoproteins (LDL) by Precipitation at Low pH: First Clinical Application of the HELP System", Klin Wochenschr (KWH), 65 (4): pp. 161-168 (1987).
26Fang, N.X. et al. , "In vivo Rapid Mobilization of Adipose Tissue by Lipid Apheresis-A Newly Developed Technique", 18<SUP>th </SUP>Australian Atherosclerosis Society Conference, Gold Cost, Australia 1992.
27Feinstone, et al., Infection and Immunity, Inactivation of Hepatitis B Virus and Non-A, Non-B Hepatitis by Chloroform, 41, 816-821. (Aug. 1983).
28Hatch et al., Lipoprotein Analysis, Advances in Lipid Research, Practical Methods for Plasma Lipoprotein Analysis, 6, 1-68. (1968).
29Horowitz, et al., Blood Coagulation and Fibrinolysis, Viral safety of solvent/detergent-treated blood products, 5, S21-S28. (1994).
30Innerarity, T.L., et al. , "Enhanced Binding by Cultured Human Fibroblasts of Apo-E-Containing Lipoproteins as Compared with Low Density Lipoproteins", Biochemistry, vol. 17: pp. 1440-1447 (1978).
31Jackson et al., Biochimica et Biophysica Acta, Isolation and Characterization of the Major Apolipoprotein from Chicken High Density Lipoproteins, 420, 342-349. (1976).
32Klimov, et al. "Extraction of Lipids from Blood Plasma and Subsequent Introduction of Autologous Delipidized Plasma into the Body as a Possible Means to Treat Artherosclerosis," English translation from the Russian Journal Kardiologiia, 1978, 18(6): 23-29.
33Koizumi, J. et al. , "Behavior of Human Apolipoprotein A-1: Phospho-Lipid and apoHDL: Phospholipid Complexes in Vitro and After Injection into Rabbits", J. Lipid Research, vol. 29: 1405-1415 (1988).
34Kostner, K. et al., "Increase of APO A1 Concentration in Hypercholesteraemic Chickens After Treatment with a Newly Developed Extracorpreal Lipid Elimination", XI Internet Symp. On Drugs Affecting Lipid Metabolism, Italy, May 13-16, 1992.
35Kostner, K. et al., "Lecithin-cholesterol acyltransferase activity in Normocholesterolaemic and Hypercholesterolaemic Roosters: Modulation by Lipid Apheresis", European Journal of Clinical Investigation, vol. 27; pp. 212-218, May 7, 1997.
36Koudinov et al., Cell Biol Int., Alzheimer's Soluble Amyloid Beta Protein is Secreted by HepG2 Cells as an Apolipoprotein, 21 (5), 265-71. (abstract only) (May 1997).
37Lupien, P.J. et al., "A New Approach to the Management of Familial Hypercholesterolaemia: Removal of Plasma-Cholesterol Based on the Principle of Affinity Chromatography", Lancet (LOS), 1 (7972)L: pp. 1261-1265 (1976).
38Moya et al., Arteriosclerosis and Thrombosis, A Cell Culture System for Screening Human Serum for Ability to Promote Cellular Cholesterol Efflux, 14 (7), 1056-1065. (Jul. 1994).
39Ngu, Medical Hypotheses, Chronic Infections from the Perspective of Evolution: a Hypothesis, 42, 81-88. (1994).
40Ngu, Medical Hypotheses, Human Cancers and Viruses: A Hypothesis for Immune Destruction of Tumours Caused by Certain Enveloped Viruses Using Modified Viral Antigens, 39, 17-21. (1992).
41Ngu, Medical Hypotheses, The viral envelope in the evoluation of HIV: a hypothetical approach to inducing an effective immune response to the virus, 48, 517-521. (1997).
42Okazaki et al., Journal of Chromatography, Biomedical Applications, Improved High-Performance Liquid Chromatographic Method for the Determination of Apolopoproteins in Serum High-Density Lipoproteins, 430, 135-142. (1988).
43Parker, T.S., et al., "Plasma High Density Lipoprotein is Increased in Man When Low Density Lipoprotein (LDL) is Lowered by LDL-Pheresis"; Proc. Nat. Acad. Sci. (USA) 83(3), pp. 777-781 (1986) (Abstract).
44Parker, Thomas S. et al. , "Plasma High Density Lipoprotein is Increased in Man When Low Density Lipoprotein (LDL) is Lowered by LDL-Pheresis", Proceedings of the National Academy of Sciences, vol. 83, pp. 777-781 (1986).
45Robern et al., Experientia, The Application of Sodium Deoxycholate and Sephacryl-200 for the Delipidation and Separation of High Density Lipoproteins, 38, 437-439. (1982).
46Ryan, W.G. et al., "An Improved Extraction Procedure for the Determination of Triglycerides and Cholesterol in Plasma or Serum", Clinical Chemistry, vol. 13: pp. 769-772 (1967).
47Scanu et al., Analytical Biochemistry, Solubility in Aqueous Solutions of Ethanol of the Small Molecular Weight Peptides of the Serum Very Low Density and High Density Lipoproteins: Relevance to the Recovery Problem During Delipidation of Serum Lipoproteins, 44, 576-588. (1971).
48Slater, H.R. et al. , "The Effect of Delipidated High Density Lipoprotein on Human Leukocyte Sterol Synthesis", Atherosclerosis, 35: pp. 41-49 (1980).
49Slater, H.R. et al., "A Comparison of Delipidated Sera Used in Studies of Sterol Synthesis by Human Mononuclear Leukocytes", J. of Lipid Research, 20: pp. 413-416 (1979).
50Thompson, G.R. et al. , "Plasma Exchange in the Management of Homozygous Familial Hypercholesterolaemia", Lancet (LOS, 1 (7918): pp. 1208-1211 (1975).
51Williams et al., Biochim. Biophys. Act., Uptake of Endogenous Cholesterol by a Synthetic Lipoprotein , 875 (2), 183-194. (Feb. 12, 1986).
52Williams, K.J. et al., "Low Density Lipoprotein Receptor-Independent Hepatic Uptake of a Synthetic, Cholesterol-Scavenging Lipoprotein: Implications for the Treatment of Receptor-Deficient Atherosclerosis", Proc. Natl. Acad. Sci. USA, vol. 85: pp. 242-246 (1988).
53Wong, et al. "Retention of gangliosides in serum delipidated by diisopropyl ether-1-butanol extraction," Journal of Lipid Research, 1983, 24, 666-669.
54Yokoyama, S. et al., "Selective Removal of Low Density Lipoprotein by Plasmapheresis in Familial Hypercholesterolemia", Arteriosclerosis (89S), 5 (6): pp. 613-622 (1985).
Référencé par
Brevet citant Date de dépôt Date de publication Déposant Titre
US80302815 mars 20084 oct. 2011Hdl TherapeuticsMethods and apparatus for creating particle derivatives of HDL with reduced lipid content
US8048015 *24 mars 20081 nov. 2011Hdl TherapeuticsMethods and apparatus for creating particle derivatives of HDL with reduced lipid content
US826878731 août 201118 sept. 2012Hdl TherapeuticsMethods and apparatus for creating particle derivatives of HDL with reduced lipid content
US863746031 août 201228 janv. 2014Hdl Therapeutics LlcMethods and apparatus for creating particle derivatives of HDL with reduced lipid content
US20040106556 *26 août 20033 juin 2004Yanhong ZhuMethod of treating and preventing alzheimer disease through administration of delipidated protein and lipoprotein particles
US20060172939 *26 oct. 20053 août 2006Marc BellottiMethods and apparatus for creating particle derivatives of HDL with reduced lipid content
US20080214438 *5 mars 20084 sept. 2008Lipid Sciences, Inc.Methods and Apparatus for Creating Particle Derivatives of HDL with Reduced Lipid Content
US20080227726 *5 mars 200818 sept. 2008Marc BellottiMethods and Apparatus for Creating Particle Derivatives of HDL with Reduced Lipid Content
US20090169591 *19 déc. 20082 juil. 2009Boston Scientific Scimed, Inc.Medical articles for the treatment of tumors
Classifications
Classification aux États-Unis604/5.03, 210/651, 604/4.01, 210/645, 422/44
Classification internationaleA61M37/00, A61M1/34, B01D11/00, A61M1/36, C02F1/44
Classification coopérativeA61M2202/0456, A61M1/3472, A61M1/3486
Classification européenneA61M1/34F
Événements juridiques
DateCodeÉvénementDescription
14 janv. 2002ASAssignment
Owner name: ARUBA INTERNATIONAL PTY. LTD., AUSTRALIA
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:CHAM, BILL ELLIOT;REEL/FRAME:012779/0827
Effective date: 20011015
17 janv. 2011REMIMaintenance fee reminder mailed
15 juin 2011LAPSLapse for failure to pay maintenance fees